Live Breaking News & Updates on Corina Dutcus

Stay updated with breaking news from Corina dutcus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer

The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient. ....

Gregory Lubiniecki , Corina Dutcus , Merck Research Laboratories , Global Clinical Development , Oncology Global Clinical Development Lead , Eisai Inc , Gynecologic Oncology , The Phase 3 Leap 001 Trial ,

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Damini Chokshi , Peter Dannenbaum , John Infanti , Gregory Lubiniecki , Julie Cunningham , Corina Dutcus , Global Clinical Development , Merck Co Inc , United States Research Laboratories , Eisai Co Ltd , United States Provide Update , First Line Treatment , Recurrent Endometrial , Vice President , United States Research , Senior Vice President , Oncology Global Clinical Development Lead , Acn Newswire ,

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Damini Chokshi , Julie Cunningham , Peter Dannenbaum , Corina Dutcus , John Infanti , Gregory Lubiniecki , Merck Co Inc , Global Clinical Development , United States Research Laboratories , Eisai Co Ltd , Vice President , United States Research , Senior Vice President , Oncology Global Clinical Development Lead ,

Eisai And Merck & Co., Inc., Rahway, NJ, USA Provide Update On Phase 3 LEAP-001 Trial Evaluating LENVIMA (Lenvatinib) Plus KEYTRUDA (Pembrolizumab) As...

Eisai And Merck & Co., Inc., Rahway, NJ, USA Provide Update On Phase 3 LEAP-001 Trial Evaluating LENVIMA (Lenvatinib) Plus KEYTRUDA (Pembrolizumab) As...
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United States , Julie Cunningham , Peter Dannenbaum , Corina Dutcus , Gregory Lubiniecki , Damini Chokshi , John Infanti , United States Research Laboratories We , Global Clinical Development , Eisai Co Ltd , Merck Co Inc , United States Provide Update , First Line Treatment , Recurrent Endometrial Carcinoma , Vice President , United States Research Laboratories , Senior Vice President , Oncology Global Clinical Development Lead , Eisai Inc ,

Merck and Eisai's Keytruda-Lenvima combo comes up short yet again, this time in endometrial cancer

Merck and Eisai's Keytruda-Lenvima combo comes up short yet again, this time in endometrial cancer
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Gregory Lubiniecki , Corina Dutcus , Merck Research Laboratories ,